The pandemic revealed supply chain vulnerabilities and spurred the Philippine government to incentivize local pharmaceutical manufacturing, especially for vaccines.

Partnerships with foreign biotech companies can produce advanced medicines domestically, reducing import reliance. The Department of Trade and Industry offers fiscal incentives for facility set-ups in special economic zones.

Public health priorities - like universal vaccination programs - align with private sector expansions of R&D labs, contract manufacturing, and distribution networks. European pharma and biotech firms with proven track records can supply technology transfers, co-invest, or contract manufacturing with local players.

Silberstein + Partners is helping companies in the healthcare and life sciences industry to take advantage of this growth opportunity. Get in touch to find out more.